Valuation AstraZeneca PLC Xetra

Stocks

Delayed Xetra 20:35:36 05/02/2026 +04			5-day change	1st Jan Change
160.70 ^EUR	+0.59%		-.--%	+1.81%

08-21	Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets	MT
08-21	Nibe a post-earnings winner on a rising Stockholm market, OMXS30 index up 0.9 percent	FW

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	182,034	209,442	209,268	203,171	287,813	258,758	-	-
Change	-	15.06%	-0.08%	-2.91%	41.66%	-10.1%	-	-
Enterprise Value (EV) ¹	206,417	232,365	231,778	227,741	311,187	278,084	270,410	261,905
Change	-	12.57%	-0.25%	-1.74%	36.64%	-10.64%	-2.76%	-3.15%
P/E	1,469x	64.1x	35.4x	29.1x	28.4x	21.4x	18.6x	16.2x
PBR	4.24x	5.65x	5.39x	5.02x	5.96x	4.8x	4.26x	3.62x
PEG	-	0x	0.4x	1.6x	0.6x	1.1x	1.3x	1.1x
Capitalization / Revenue	4.87x	4.72x	4.57x	3.76x	4.9x	4.09x	3.87x	3.63x
EV / Revenue	5.52x	5.24x	5.06x	4.21x	5.3x	4.4x	4.05x	3.67x
EV / EBITDA	27.2x	25.2x	17.1x	13.6x	16x	12.5x	11.1x	9.8x
EV / EBIT	20.8x	17.4x	15.9x	13.5x	16.8x	13.2x	11.6x	10.2x
EV / FCF	42.4x	26.7x	25.8x	22.9x	26.5x	29.5x	20.8x	18.1x
FCF Yield	2.36%	3.75%	3.88%	4.36%	3.78%	3.39%	4.8%	5.52%
Dividend per Share ²	2.87	2.9	2.9	3.1	3.2	3.325	3.528	3.662
Rate of return	2.44%	2.15%	2.15%	2.37%	1.72%	1.99%	2.11%	2.2%
EPS ²	0.08	2.11	3.81	4.5	6.54	7.807	8.959	10.31
Distribution rate	3,588%	137%	76.1%	68.9%	48.9%	42.6%	39.4%	35.5%
Net sales ¹	37,417	44,351	45,811	54,073	58,739	63,248	66,838	71,269
EBITDA ¹	7,586	9,237	13,580	16,691	19,476	22,271	24,391	26,737
EBIT ¹	9,928	13,350	14,534	16,928	18,478	21,047	23,260	25,555
Net income ¹	112	3,288	5,961	7,035	10,225	12,070	13,716	15,668
Net Debt ¹	24,383	22,923	22,510	24,570	23,374	19,326	11,652	3,147
Reference price ²	117.51	135.16	135.02	131.05	185.60	166.83	166.83	166.83
Nbr of stocks (in thousands)	1,549,159	1,549,528	1,549,926	1,550,317	1,550,726	1,551,024	-	-
Announcement Date	10/02/22	09/02/23	08/02/24	06/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	35.55x	12.84x	26.06x	0.55%	1,109B
JOHNSON & JOHNSON	29.74x	-	-	2.01%	644B
ABBVIE INC.	33.42x	7.74x	16.11x	2.62%	463B
ROCHE HOLDING AG	20.72x	4.91x	12.16x	2.69%	371B
NOVARTIS AG	22.47x	5.78x	14.33x	2.76%	301B
ASTRAZENECA PLC	21.12x	4.35x	12.35x	2.02%	256B
AMGEN INC.	27.43x	7.09x	12.59x	2.33%	234B
NOVO NORDISK A/S	13.47x	4.79x	10.05x	3.81%	205B
GILEAD SCIENCES, INC.	-43.83x	6.34x	24.76x	2.3%	178B
Average	17.79x	6.73x	16.05x	2.34%	417.9B
Weighted average by Cap.	25.34x	8.43x	18.53x	1.91%